What is the black box warning for forxiga?

What conditions are associated with the black box warning for Forxiga?

The medication dapagliflozin, marketed as Forxiga [1], carries a black box warning for increased risk of amputations, particularly of the toes.

What happens if patients do not have proper monitoring for amputations?

Patients taking Forxiga are at a higher risk of foot ulcers, which may lead to amputation if not properly managed and monitored [2]. This includes regular foot exams to check for signs of ulcers, wounds, or calluses that could become infected.

Why is this risk associated with Forxiga specifically?

Forxiga belongs to a class of medications called SGLT2 inhibitors, which increase the risk of amputations. SGLT2 inhibitors work by blocking the reabsorption of glucose in the kidneys, thereby increasing glucose excretion in the urine. While they are effective in managing type 2 diabetes, this side effect profile is a concern for long-term use [3].

How do patients and healthcare providers mitigate the risk of amputations?

Proper monitoring, regular foot exams, and addressing any signs of ulcers or wounds immediately can significantly reduce the risk of amputation in patients taking Forxiga. Additionally, healthcare providers should discuss the risks and benefits of Forxiga with patients and assess the individual's risk factors for foot ulcers or amputation [4].

Sources:

[1] Forxiga (dapagliflozin) prescribing information. AstraZeneca.
[2] FDA prescribing information: Farxiga (dapagliflozin).
[3] DrugPatentWatch.com - Dapagliflozin.
[4] FDA warning letter on increased risk of amputations with SGLT2 inhibitors.